ADC Therapeutics logo

ADC Therapeutics

Innovating Science. Inspiring Hope.

266 employees · est. 2011 · Lausanne, Switzerland

VS
Ambrx logo

Ambrx

Pioneer and Leader in Next Generation Antibody Drug Conjugates Using Engineered Precision Biologics

58 employees · est. 2003 · San Diego, United States

Ambrx is the older company (2011 vs 2003); ADC Therapeutics is the larger of the two.

Side-by-Side Comparison

ADC Therapeutics Ambrx
Founded
2011 2003 older
Headquarters
Lausanne, Switzerland San Diego, United States
Employees
266 larger 58
Industry
Biopharma, Biotechnology, Health and Wellness Biotechnology
Funding Stage
Unknown Acquired
Total Funding
$1.27B $2.55B
Funding Rounds
13 11
Services
Development of Antibody Drug Conjugates, Expansion of Cancer Treatment Products, Clinical Trial Innovation, Medical Affairs and Research Not tracked yet
Target Customers
Patients with Hematologic Cancers, Patients with Solid Tumors, Individuals with Relapsed or Refractory Cancer, Healthcare Providers in Oncology Not tracked yet
Taxonomy
Antibody Drug Conjugates (ADCs), Oncology, Hematological Cancers, Solid Tumors, Clinical-Stage Drug Development, Commercialization, CD19-directed Therapies, ZYNLONTA®, Pyrrolobenzodiazepine (PBD) Technology, Relapsed Or Refractory Diffuse Large B-cell Lymphoma, PSMA-targeting ADC, Cancer Treatment, Pharmaceutical Manufacturing, Drug Discovery, Biotechnology Innovation Antibody Drug Conjugates, Next Generation Therapies, Precision Biologics, Genetic Code Expansion, Immune System Modulation, Cancer Treatment, Prostate-Specific Membrane Antigen, HER2 Targeting, Protein Engineering, Biopharmaceutical Development, Clinical Stage Programs, Preclinical Programs
Website
adctherapeutics.com ambrx.com
ADC Therapeutics logo

About ADC Therapeutics

ADC Therapeutics, based in Switzerland, is a commercial-stage global leader in antibody drug conjugates (ADCs), dedicated to transforming cancer treatment. Founded in 2011, the company's expertise spans clinical development to manufacturing. With a focus on pioneering the ADC sector, their approved...

Ambrx logo

About Ambrx

Ambrx, founded in 2003 as a spin-out from The Scripps Research Institute, is a clinical stage biopharmaceutical company listed on Nasdaq under the ticker AMAM. Positioning itself as a pioneer and leader in its field, Ambrx employs an innovative expanded genetic code technology platform to develop ne...

We will tell you when either one moves

BounceWatch watches ADC Therapeutics and Ambrx for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at ADC Therapeutics and Ambrx — by email.

Frequently Asked Questions

ADC Therapeutics — Innovating Science. Inspiring Hope. . Ambrx — Pioneer and Leader in Next Generation Antibody Drug Conjugates Using Engineered Precision Biologics. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
ADC Therapeutics has raised $1.27B while Ambrx has raised $2.55B.
ADC Therapeutics and Ambrx operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare ADC Therapeutics with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at ADC Therapeutics on 10 Jun 2026, and Ambrx on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy